Anzeige
Mehr »
Samstag, 01.11.2025 - Börsentäglich über 12.000 News
Attestation ist die Killer-App - Republic baut sie jetzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4LY | ISIN: US00773J2024 | Ticker-Symbol: 3920
Tradegate
31.10.25 | 14:55
21,200 Euro
0,00 % 0,000
1-Jahres-Chart
SPYRE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SPYRE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
21,00021,20031.10.
20,80021,40031.10.

Aktueller Chart SPYRE THERAPEUTICS Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
SPYRE THERAPEUTICS INC-Investoren interessieren sich auch für diese Wertpapiere
Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended...
► Artikel lesen
Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateFirst patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase...
► Artikel lesen
Oruka Therapeutics, Inc.: Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in SeptemberIND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to...
► Artikel lesen
Palvella Therapeutics Inc.: U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic MalformationsSecond year proceeds granted following FDA review of annual performance progress report on Phase 3 SELVA single-arm, baseline-controlled trial; up to $2.6 million in non-dilutive funding anticipated...
► Artikel lesen
Palvella Therapeutics Inc.: Palvella Therapeutics Announces Expansion of QTORIN Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved therapiesClinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the...
► Artikel lesen
Palvella Therapeutics Inc.: Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN Rapamycin for Cutaneous Venous MalformationsPhase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most...
► Artikel lesen